DEC 05, 2017 6:00 AM PST

WEBINAR: Androgen signaling in advanced prostate cancer models using noninvasive hyper polarized MRI and mass spectrometry

Sponsored by: Agilent
Speaker
  • Associate Professor, Department of Genitourinary Medical Oncology
    Biography
      Dr. Titus earned his Ph.D. from the University of Washington, Seattle Washington and completed his postdoctoral research in the Laboratories for Reproductive Biology, University of North Carolina School of Medicine at Chapel Hill, North Carolina. His initial faculty appointment was in the Department of Urology at Roswell Park Cancer Center, Buffalo NY. In 2012, Dr. Titus joined the faculty in Genitourinary Medical Oncology at MD Anderson Cancer Center.

    Abstract

    DATE: December 5th, 2017
    TIME:  6:00AM PT

    Androgen receptor (AR) signaling remains a driver in the lethal phenotype of prostate cancer, castrate resistant prostate cancer (CRPC). Novel second generation enhanced androgen inhibitors, abiraterone acetate and enzalutamide, improve survival of CRPC patients following androgen deprivation therapy. However, a significant group of patients demonstrate primary resistance to these agents and other patients acquire resistance during therapy. The mechanisms of enhanced androgen inhibitor resistance are complex. AR-dependent mechanisms involve AR overexpression, AR mutation, intra-tumor ligand biosynthesis, modulation of co-activators and co-repressors and expression of AR spice variants. AR-independent tumors activate glucocorticoid receptor and differentiate to aggressive variant or neuroendocrine phenotype with loss of tumor suppressors.  Patient derived xenografts (PDX) developed from men with AR-positive or AR-negative CRPC were used to determine impact of AR signaling on glycolysis. We used two AR positive (MDA-PCa-133 and 180-30) and 2 AR negative (MDA-PCa-144 and 155) PDX grown in intact male mice. In vivo hyperpolarized MRI of each PDX was performed at a tumor volume of ~1.0 cm3 using 1-[13C]-pyruvate conversion to 1-[13C]-lactate. Ex vivo measurement of glycolytic metabolites, lactate, tricarboxylic acids and unique cancer metabolites were determined using NMR and mass spectrometry. We found increased glycolysis and alterations in other bioenergy metabolites in AR-positive PDX models and in low androgen environment (castration) versus AR-negative models. Our research supports the potential of hyperpolarized metabolic imaging in determining the underlying biology and in vivo phenotyping of CRPC.  

    Learning Objectives:

    • the link between hyperpolarized imaging and quantitative mass spectrometry – proof of principle
    • metastatic prostate cancer being a diverse disease
    • analytical instrumentation in diagnostic and predictive marker development

     

    For Research Use Only. Not for use in diagnostic procedures.

     


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 21, 2021 5:00 PM CEST
    APR 21, 2021 5:00 PM CEST
    Date: April 21, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Spatial Answers Trilogy - Spatial Answers in Immunology Immunology Researchers share their Spatial Discoveries in SARS-C...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    DEC 16, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    DEC 05, 2017 6:00 AM PST

    WEBINAR: Androgen signaling in advanced prostate cancer models using noninvasive hyper polarized MRI and mass spectrometry

    Sponsored by: Agilent

    Specialty

    Cancer Research

    Molecular Biology

    Genetics

    Cell Biology

    Biotechnology

    Immunology

    Biochemistry

    Biomarkers

    Cancer Therapeutics

    Laboratory Testing

    Clinical Research

    Cancer Diagnostics

    Clinical Diagnostics

    Molecular Diagnostics

    Bioinformatics

    Geography

    North America63%

    Europe19%

    Asia7%

    South America5%

    Africa3%

    Oceania1%

    Registration Source

    Website Visitors99%

    Email Promotions1%

    Website Banners1%

    Job Title

    Medical Laboratory Technician13%

    Educator/Faculty11%

    Executive11%

    Medical Doctor/Specialist9%

    Clinical Laboratory Scientist9%

    Research Scientist9%

    Facility/Department Manager8%

    Student7%

    Scientist5%

    Marketing/Sales4%

    Chemist4%

    Lab Management4%

    Post Doc4%

    Biologist2%

    Organization

    Academic Institution12%

    Clinical Laboratory10%

    Life Science Company5%

    Biotech Company5%

    Hospital5%

    Research Institute4%

    Pharmaceutical Company3%

    Consultant3%

    Medical Center3%

    Government3%

    Non-Profit Organization3%

    Media2%

    Medical School2%

    Ambulatory Care2%

    Other4%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more